AngioGenex, Inc. operates as a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration. The company was founded by Michael M. Strage and Robert Benezra in March 1999 and is headquartered in New York, NY.